Advanced Monitoring Platform Tracks Hemodynamic Data
By HospiMedica International staff writers Posted on 08 May 2017 |
Image: The HemoSphere advanced monitoring platform (Photo courtesy of Edwards Lifesciences).
Innovative technology provides exceptional clarity of patient hemodynamics, helping clinicians make proactive, timely clinical decisions.
The Edwards Lifesciences HemoSphere advanced monitoring platform is designed to provide an informative and comprehensive hemodynamic profile of hospitalized patients by unremittingly assessing continuous cardiac output (CCO), blood pressure (BP), pulse, right ventricular ejection fraction (RVEF), right ventricular end-diastolic volume (RVEDV), and venous oxygen saturation (SVO2), which is considered one of the earliest indicators of a threat to tissue oxygenation.
The scalable system introduces adaptive expansion modules, and can be used with both Swan-Ganz pulmonary artery catheters and oximetry catheters, and with the Edwards triple lumen oximetry central venous catheter (CVC) that provides continuous monitoring of central venous oxygen saturation (ScvO2). The HemoSphere advanced monitoring platform includes high-quality, visual clinical support screens and an intuitive touch screen, which can be adapted to meet the needs of the care environment. The system is also wireless-enabled for continuous data transfer.
“Representing the next generation of hemodynamic monitoring, the HemoSphere advanced monitor builds on Edwards' more than 50 years of experience in providing clinicians with technology and education to help improve patient care, and lays the foundation for future advancements in hemodynamic monitoring,” said Catherine Szyman, corporate vice president for critical care at Edwards Lifesciences.
“The HemoSphere advanced monitor enables simplified visual clinical support, which is particularly important in the care of our most complex, critically ill patients,” said Davinder Ramsingh, MD, of Loma Linda University Medical Center (CA, USA). “Clinicians can choose the clinical support screens that best suit their needs and monitor the pressures and blood flow of the right heart as conditions change, informing potentially life-saving decisions on behalf of their patients.”
Hemodynamic monitoring combined with oxygen transport assessment is used to differentiate the relative magnitude of pulmonary and cardiovascular dysfunction contributing to hypoxemia. All patients admitted to the intensive care unit (ICU) require standard basic hemodynamic monitoring, which includes an electrocardiogram (ECG), heart rate, blood pressure, central venous pressure, temperature, peripheral venous oxygen saturation, and blood gas analysis.
The Edwards Lifesciences HemoSphere advanced monitoring platform is designed to provide an informative and comprehensive hemodynamic profile of hospitalized patients by unremittingly assessing continuous cardiac output (CCO), blood pressure (BP), pulse, right ventricular ejection fraction (RVEF), right ventricular end-diastolic volume (RVEDV), and venous oxygen saturation (SVO2), which is considered one of the earliest indicators of a threat to tissue oxygenation.
The scalable system introduces adaptive expansion modules, and can be used with both Swan-Ganz pulmonary artery catheters and oximetry catheters, and with the Edwards triple lumen oximetry central venous catheter (CVC) that provides continuous monitoring of central venous oxygen saturation (ScvO2). The HemoSphere advanced monitoring platform includes high-quality, visual clinical support screens and an intuitive touch screen, which can be adapted to meet the needs of the care environment. The system is also wireless-enabled for continuous data transfer.
“Representing the next generation of hemodynamic monitoring, the HemoSphere advanced monitor builds on Edwards' more than 50 years of experience in providing clinicians with technology and education to help improve patient care, and lays the foundation for future advancements in hemodynamic monitoring,” said Catherine Szyman, corporate vice president for critical care at Edwards Lifesciences.
“The HemoSphere advanced monitor enables simplified visual clinical support, which is particularly important in the care of our most complex, critically ill patients,” said Davinder Ramsingh, MD, of Loma Linda University Medical Center (CA, USA). “Clinicians can choose the clinical support screens that best suit their needs and monitor the pressures and blood flow of the right heart as conditions change, informing potentially life-saving decisions on behalf of their patients.”
Hemodynamic monitoring combined with oxygen transport assessment is used to differentiate the relative magnitude of pulmonary and cardiovascular dysfunction contributing to hypoxemia. All patients admitted to the intensive care unit (ICU) require standard basic hemodynamic monitoring, which includes an electrocardiogram (ECG), heart rate, blood pressure, central venous pressure, temperature, peripheral venous oxygen saturation, and blood gas analysis.
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration